Sustained Virological Response Following an 11 Day Course of Direct Acting Antiviral Therapy for Hepatitis C Infection
David Yardeni, Vitaliy Dizengof, Anat Nevo-Shor, Naim Abufreha, Harel Dahari and Ohad Etzion
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES
Direct acting anti-viral medications have revolutionized the treatment of chronic Hepatitis C (HCV). Eradication is now feasible following 8-12 weeks of direct acting antiviral (DAA) treatment. This presentation highlights the eradication of HCV with only 11 days of DAA treatment. A 63-year-old woman with chronic HCV was prescribed treatment with Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir (3D) for 12 weeks. On day 11 of treatment the patient began suffering from severe weakness and muscle rigidity and discontinued treatment. HCV RNA test performed 30 days after treatment initiation was found to be negative. Repeat HCV RNA testing at 12 and 24 weeks post treatment cessation were also negative. Thus, HCV eradication was achieved with only 11 days of DAA treatment. This suggests that further investigations are needed to identify patients suitable for a shorter treatment course.